Review: Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ

This year, after two long years of convening virtually, it was great to see so many unite in the city of New Orleans for #AACR2022.

It is clear that “zoom fatigue” has set in, and some of the novelty of virtual conferences has worn off in the past year; having said that, they are likely here to stay, even as in-person events return with hybrid events in 2022.

GEN: If I were to design my own panel for immunofluorescence, what are the main considerations, given everything you’ve suggested during the webinar for validation? Angela: There are several things one needs to think about when you build a new panel for multiplexed immunofluorescence. You need to consider the abundance of the targets to be

Despite advances in immunotherapy, it’s clear that only a minority of patients respond. Therapies that rely on immune activation, such as checkpoint inhibitors, have been shown to be especially difficult due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Clearly there’s much anticipation and focus on new contenders for successful combination checkpoint therapy.

Alfred Hitchcock once said, “The more successful the villain, the more successful the picture”, for the immunotherapy picture, that successful villain is M1 macrophages.

If you stand too close to the painting for too long observing all the details, you begin to lose sight of what those brush strokes have created. Only when you step back to take in the scene can you have a full understanding and appreciation for how the individual elements come together to create a work of art.

It was a record year of attendance at this year’s 37th annual SITC meeting. Whether reflective of waning new Covid cases from a peak in late January 2022, a new location, or merely the appetite to meet up with colleagues, check out new technologies or be part of important scientific discussions-Boston SITC had it all.

As I approach my one-year anniversary with Ultivue, I am excited to be part of a vibrant, rapidly growing company committed to transforming anatomic pathology with our next generation staining technology, InSituPlex®.